Raremark operates a patient-engagement and data-analysis platform focused on rare diseases, using machine-learning to engage and retain patients and their families. The platform provides biopharmaceutical companies access to anonymized and aggregated patient data to inform clinical development. Raremark aims to reduce the time and cost of clinical trials by improving trial design and yielding higher-quality insights into disease mechanisms, symptoms and heterogeneity. The company positions its technology to raise health literacy and informed participation in medical research. The recent funding will be used to further develop its patient-engagement and data-analysis technology to help identify, engage and learn from patients. Raremark is headquartered in London and also maintains an office in Boston, US.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2018